Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FLM-7523
- Development stage
- Preclinical
- Lead developer
- Flamingo Therapeutics
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
FLM-7523 is a clinical-stage antisense oligonucleotide (ASO) developed by Flamingo Therapeutics in collaboration with Ionis Pharmaceuticals. This RNA-targeted therapy is designed to inhibit the Androgen Receptor, with the aim of treating oncology indications. The drug was part of an alliance where Flamingo Therapeutics acquired rights to several clinical-stage ASO programs from Ionis, leveraging both companies' expertise in RNA-targeted drug discovery and oncology.
- Other names
- MALAT1 RNA-targeted therapyMALAT-1 RNA-targeted therapyMALAT 1 RNA-targeted therapyMALAT1 targeted ASOMALAT-1 targeted ASOMALAT 1 targeted ASO
02
Targets
MALAT1 (Metastasis associated lung adenocarcinoma transcript 1)
Beyond the preview
Go deeper on FLM-7523.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FLM-7523.